Therapy Areas: Diabetes
Innovent Biologics doses first type 2 diabetes patient in IBI362 phase two clinical trial
8 September 2021 -

Innovent Biologics Inc (HKEX: 01801), a China-based biopharmaceutical company, announced on Tuesday that it has dosed its first type 2 diabetes patient in a phase two clinical trial (clinicaltrials.gov, NCT04965506) of IBI362, a glucagon-like peptide 1 receptor (GLP-1R) and glucagon receptor (GCGR) dual agonist in China.

The randomised, multicentre phase two clinical trial is to assess the efficacy and safety of IBI362 compared with placebo and dulaglutide in patients with type 2 diabetes in China. The main aim of the study is to assess change from baseline in HbA1c level after 20-week dosing in patients with type 2 diabetes inadequately controlled with lifestyle intervention or metformin.

The product is a synthetic long-acting mammalian oxyntomodulin analogue and is a GLP-1R and GCGR dual agonist. It uses a fatty acyl side chain to prolong the duration of action, allowing once-weekly dosing.

Login
Username:

Password: